NCT05044026View on ClinicalTrials.gov

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

CompletedOBSERVATIONAL
Enrollment

1,012

Participants

Timeline

Start Date

September 20, 2012

Primary Completion Date

September 19, 2022

Study Completion Date

September 19, 2022

Conditions
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Interventions
OTHER

Jakavi

Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.

Trial Locations (1)

52074

Novartis Investigative Site, Aachen

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY